With the introduction of immunotherapy, significant improvement has been made in the
treatment of head and neck squamous cell carcinoma (HNSCC). However, only a small …

Anti-programmed cell death protein 1 (PD-1) agents have become the standard of care for
platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) …

Preclinical data suggest that head and neck squamous cell carcinoma (HNSCC) is a
profoundly immunosuppressive disease, characterized by abnormal secretion of …

Head and neck cancers are a group of diverse and heterogeneous tumors, among which
squamous cell carcinoma of the head and neck (SCCHN) is the most prevalent. Current …

Simple Summary Squamous cell cancer of the head and neck is a common malignancy with
poor prognosis. Despite the success of PD-L1 expression, the landscape of diagnostic …

Head and neck cancer (HNC) is the sixth most common cancer type, accounting for
approximately 277,597 deaths worldwide. Recently, the Food and Drug Administration …

Opinion statement The discovery and antibody targeting of immune regulatory molecules
such as programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 …

Preclinical data suggest that head and neck squamous cell carcinomas (HNSCC) may
evade immune surveillance and induce immunosuppression. One mechanism of immune …

Recurrent locally advanced or metastatic head and neck squamous cell carcinoma
(HNSCC) is associated with dismal prognosis because of its highly invasive behavior and …

Background Immune checkpoint inhibitors targeting the programmed cell death protein 1
(PD‐1)/programmed cell death ligand 1 (PD‐L1) pathway have recently emerged as a …